ArticleSmall science2026
Novel Respiratory Disease Diagnosis Tool: Development of an Au-ReS
Article in Small science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recent Progress in Artificial Intelligence in Biosensor Development: From Bioprobe Design to Fabrication and Signal Analysis.Biosensors · 2026Review
- Development of a Sandwich-TypeBiosensors · 2026Article
- Novel Respiratory Disease Diagnosis Tool: Development of an Au-ReSSmall science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spirometry is influenced by the patient's subjective condition, which limits the reproducibility of diagnostic results despite being a key diagnostic tool for respiratory diseases. To overcome this, an extended-gate field-effect transistor-type aptasensor for detecting granzyme B (GzmB) and perforin (PRF) is introduced as a proof-of-concept for diagnosing localized immune responses in respiratory diseases. The novel GzmB and PRF aptamers are synthesized using systematic evolution of ligands by exponential enrichment and are subsequently truncated to enhance the target-binding affinity. Au-ReS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.